BLFS
BIOLIFE SOLUTIONS INC
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$36.69
−0.43%Sep 8, 2026, 22:00 UTC
Repligen and BioLife Solutions received US antitrust approval for their $1.5 billion merger as the Hart-Scott-Rodino waiting period expired on September 3, 2026.
Source:Aug 6, 2026, 20:03 UTC
Repligen announced it will acquire BioLife Solutions, with the transaction expected to close in the fourth quarter of 2026.
Source:Aug 6, 2026, 20:03 UTC
BioLife Solutions reported second quarter 2026 financial results with total revenue of $28.5 million, up 21% year-over-year, GAAP net income of $45.1 million including a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million.
Source:Jul 22, 2026, 10:00 UTC
Repligen agreed to acquire BioLife Solutions to expand its cell therapy capabilities with biopreservation media.
Jun 27, 2026, 16:20 UTC
BioLife has drawn takeover interest from Repligen.